Artificial intelligence is dramatically speeding up drug development — and a proprietary survey shows how it's priming a bigger automation push that's changing the trajectory of early stage pharma research. Why it matters: The TD Cowen survey of 80 biopharma leaders and insiders finds AI is compressing drug developers' preclinical costs and timelines by as much as 70%. - That's fueling demand for cutting-edge software, sequencing tools and computer models that will help churn out more experimental treatments in the next five years. The big picture: AI can't replace scientific intuition. But the way it can streamline the grueling R&D before human testing begins is making computer screens as important a feature of drug design as…
What are the primary threats to U.S. research efforts mentioned in the report?
China's biotech buildup threatens U.S. research efforts by offering cheaper labor and quick turnaround times, which are attracting billions in new investment.
15220119-eb77-46eb-b68c-d77e336ab2dd
What is the current status of AI-discovered drugs regarding FDA approval?
AI has not yet discovered a drug that has won Food and Drug Administration (FDA) approval.
76b2efc8-c4b2-4862-9656-4c58f8619466
What specific types of software are expected to see the strongest upside in demand by 2028?
Demand is expected to be strongest for advanced software that can simulate biological processes, predict how two drugs interfere with each other, or adjust dosages for pregnant women and newborns.
f7d295a1-69c3-40e3-a388-36a9071f59b4
How might the Trump administration's push to reduce animal testing in biomedical research influence pharmaceutical research methods?
It will likely pivot more work toward computational tools, 3D human tissue models, and other alternatives that predict the toxicity of a compound.
cd8ef136-23bb-4b34-b8ce-fc834cdeec18
What are the projected growth rates and spending increases for new drug development programs according to TD Cowen survey data?
New drug development programs could grow by more than 10% in the next three to five years, and the technology buying spree and lab spending could account for an additional $1 billion in incremental spending.
5d21de05-d211-47ed-ba25-81c3ee68b16f
According to a TD Cowen survey of 80 biopharma leaders and insiders, how is artificial intelligence affecting preclinical costs and timelines for drug developers?
AI is compressing preclinical costs and timelines by as much as 70%.
0a0c7e90-da29-4737-accd-fb818796a04a